OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
OncoMed Pharmaceuticals (OMED) PT Lowered to $15 at Jefferies
May 6, 2016 8:03 AM EDTJefferies analyst Brian Abrahams kept a Buy rating but lowered his price target on OncoMed Pharmaceuticals (NASDAQ: OMED) to $15.00 (from $16.00) following Q1 results.
Abrahams commented, "OMED's financials and clinical trial progress were mostly in line for the quarter, and while more key data... More
OncoMed Pharma (OMED) Misses Q1 EPS by 17c
May 5, 2016 5:20 PM EDTOncoMed Pharma (NASDAQ: OMED) reported Q1 EPS of ($0.90), $0.17 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.28 million.
For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.
... More